| scholarly article | Q13442814 |
| P2093 | author name string | Manoj Kumar | |
| Rakhi Maiwall | |||
| P2860 | cites work | Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation | Q80031512 |
| Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation | Q82888234 | ||
| Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy | Q83204702 | ||
| Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation | Q84208480 | ||
| Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation | Q84437496 | ||
| Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation | Q86215837 | ||
| Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin | Q86283839 | ||
| Long-term observation of osteomalacia caused by adefovir-induced Fanconi's syndrome | Q87326459 | ||
| Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus | Q21128797 | ||
| Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation | Q24234338 | ||
| Hepatitis B virus morphogenesis | Q24563883 | ||
| Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions | Q24674767 | ||
| Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence | Q26799246 | ||
| The option of HBIG-free prophylaxis against recurrent HBV | Q26995972 | ||
| Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection | Q27333253 | ||
| Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis | Q28348802 | ||
| Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. | Q30391932 | ||
| Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation | Q30431207 | ||
| Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization | Q30468279 | ||
| A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. | Q31921588 | ||
| An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy | Q34085342 | ||
| Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review | Q34091164 | ||
| Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease | Q34094783 | ||
| Contradictory immune response in post liver transplantation hepatitis B and C. | Q34152074 | ||
| Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation | Q34200824 | ||
| The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. | Q34318146 | ||
| Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. | Q34462234 | ||
| Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression | Q35126674 | ||
| Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis | Q35549423 | ||
| Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations | Q35811558 | ||
| Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis | Q36382193 | ||
| Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin | Q36778844 | ||
| Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection | Q36883851 | ||
| GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees | Q36950984 | ||
| Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis | Q37328605 | ||
| Control of cccDNA function in hepatitis B virus infection. | Q37555389 | ||
| Liver grafts from anti-hepatitis B core positive donors: a systematic review | Q37662582 | ||
| Managing HBV in patients with impaired immunity | Q37762927 | ||
| Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. | Q37886893 | ||
| High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. | Q38058545 | ||
| Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation | Q38177252 | ||
| Strategies to inhibit entry of HBV and HDV into hepatocytes. | Q38207387 | ||
| The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection | Q38219409 | ||
| Prevention of hepatitis B virus reinfection in liver transplant recipients | Q38230757 | ||
| Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease | Q38908763 | ||
| Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine | Q39038794 | ||
| Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor | Q39051196 | ||
| Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation | Q39340555 | ||
| Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes | Q39723280 | ||
| Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions | Q39811034 | ||
| Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. | Q40142447 | ||
| Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. | Q40780181 | ||
| Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis? | Q42164812 | ||
| Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin | Q42173073 | ||
| Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma | Q42278229 | ||
| Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin | Q42540557 | ||
| Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection | Q42752143 | ||
| Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection | Q42797242 | ||
| Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence | Q43033446 | ||
| One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis | Q43056952 | ||
| HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients | Q43267306 | ||
| Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus | Q43293049 | ||
| Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients | Q43413673 | ||
| Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor | Q43510521 | ||
| Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection | Q43672287 | ||
| Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis | Q43672289 | ||
| Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study | Q43756998 | ||
| Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation | Q43783661 | ||
| Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation | Q43828638 | ||
| Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis | Q43851685 | ||
| Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease | Q44005582 | ||
| Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation? | Q44033386 | ||
| De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation | Q44033724 | ||
| Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors | Q44321135 | ||
| A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation | Q44451378 | ||
| HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis | Q44493743 | ||
| Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. | Q44863613 | ||
| Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants | Q44909993 | ||
| HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence | Q45273548 | ||
| Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. | Q45299212 | ||
| Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates | Q45352399 | ||
| Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection | Q45368686 | ||
| Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients | Q45387428 | ||
| Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. | Q45395704 | ||
| Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. | Q45396940 | ||
| Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence | Q45400039 | ||
| Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy | Q45406895 | ||
| Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence | Q45495851 | ||
| Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection | Q45746042 | ||
| Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. | Q45748634 | ||
| High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation | Q45749994 | ||
| Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis | Q45749995 | ||
| In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen | Q45762700 | ||
| The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. | Q45767731 | ||
| Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. | Q45832785 | ||
| A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis | Q46313699 | ||
| Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy | Q46720792 | ||
| Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. | Q50889818 | ||
| Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Q57791894 | ||
| Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B | Q58802765 | ||
| Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin | Q71821516 | ||
| Liver transplantation in European patients with the hepatitis B surface antigen | Q72623987 | ||
| Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens | Q77828279 | ||
| Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation | Q79822782 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver transplantation | Q1368191 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 54-65 | |
| P577 | publication date | 2016-03-28 | |
| P1433 | published in | Journal of clinical and translational hepatology | Q27726496 |
| P1476 | title | Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation | |
| P478 | volume | 4 |
| Q41706808 | Current Scenario of Hepatitis B and Its Treatment in India. |
| Q50326421 | Hepatitis B Virus Infection and Organ Transplantation |
| Q47547024 | Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globülin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients. |
Search more.